Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061035 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma
A Phase 1 study of Prostatic Neoplasms, sponsored by Cosmo Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00061035: Completed Phase 1 study of Prostatic Neoplasms, sponsored by Cosmo Bioscience.
NCT00061035 is a Phase 1 study of Prostatic Neoplasms that has completed, run by Cosmo Bioscience. The registered enrollment target is 18 participants, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00061035, a Phase 1 study of Prostatic Neoplasms, has completed, sponsored by Cosmo Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Dr. Frederick Millard, MD, Associate Clinical Professor at the UCSD Cancer Center, will be conducting a 12-week study in advanced prostate cancer patients. The study will be held at the UCSD Medical Center and will test an experimental investigational gene therapy vaccine designed to make the patient's immune system react against telomerase, an enzyme expressed in prostate cancer cells.
Conditions Studied
Interventions
- BIOLOGICAL Transgenic Lymphocyte Immunization Vaccine (TLI)
Study Locations (1)
California
- University of California, San Diego Cancer Center - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2003-04 |
| Phase | Phase 1 |
What the finished NCT00061035 record still lists
NCT00061035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Transgenic Lymphocyte Immunization Vaccine (TLI) is the first listed.
NCT00061035 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00061035 about?
NCT00061035 is a clinical study titled "Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma". Dr. Frederick Millard, MD, Associate Clinical Professor at the UCSD Cancer Center, will be conducting a 12-week study in advanced prostate cancer patients. The study will be held at the UCSD Medical Center and will test an experimental investigational gene therapy vaccine designed to make the patien...
What is the current status of trial NCT00061035?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2003-04.
What conditions does trial NCT00061035 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT00061035?
The interventions under investigation include: Transgenic Lymphocyte Immunization Vaccine (TLI) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00061035?
This trial is sponsored by Cosmo Bioscience, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00061035 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00061035's enrollment target sits among peer trials
18 61st of 65 higher than 5 of 65 other Prostatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
RECRUITING · Phase 1
-
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
RECRUITING · Phase 1
-
A Study of DM002 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia